CCO Independent Conference Highlights of the 2024 San Antonio Breast Cancer Symposium *

Review a ClinicalThought commentary, summary slidesets, and a CME-certified expert analysis of key data from the 2024 San Antonio Breast Cancer Symposium (2024 SABCS).

Share

Program Content

Activities

SABCS 2024 Top Abstracts
An Expert’s Guide to SABCS 2024: A Preview of the Top Abstracts
Clinical Thought
Conference Coverage
Congratulations: You achieved a completion on 04/09/2022

Released: December 06, 2024

Expires: December 05, 2025

10 Capsule Summaries

Activities

EMBER 3
EMBER-3: Imlunestrant ± Abemaciclib vs SoC ET in Patients With ER+/HER2- ABC After Progression on Prior ET
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 13, 2024

Expires: June 12, 2025

KEYNOTE 522 Subgroup Analyses
KEYNOTE-522: Biomarker and OS Subgroup Analyses of Neoadjuvant Pembrolizumab + CT Followed by Adjuvant Pembrolizumab in High-Risk Early TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: June 15, 2025

SOLTI VALENTINE
Phase II SOLTI VALENTINE: Neoadjuvant HER3-DXd ± Letrozole for High-Risk HR+/HER2- EBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 16, 2024

Expires: June 15, 2025

PADMA
PADMA: ET + Palbociclib vs Standard Chemotherapy in High-Risk HR+/HER2- MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

ELECTRA and ELEVATE
ELECTRA and ELEVATE: Elacestrant Combinations for ER+/HER2- Advanced/Metastatic Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

neoHIP
neoHIP: Phase II Trial of Neoadjuvant Pembrolizumab + HER2-Targeted Therapy for HER2-Positive Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 17, 2024

Expires: June 16, 2025

DESTINY Breast06 Subgroup Analysis
DESTINY-Breast06: T-DXd vs Chemotherapy by Pace of Progression on Previous ET in Patients With HR+/HER2-Low or HER2-Ultralow MBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: June 17, 2025

RIGHT Choice
RIGHT Choice: Subgroup Analyses From the Phase II Trial of First-line Ribociclib + ET vs Combination Chemotherapy in Clinically Aggressive HR+/HER2- Advanced Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: June 17, 2025

OlympiA 10 Year Follow Up
OlympiA: 10-Yr Follow-up With Adjuvant Olaparib in Patients With gBRCA1/2-Mutated HER2-Negative Early Breast Cancer
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: June 17, 2025

GBG 96 GeparDouze
NSABP B-59/GBG-96-GeparDouze: Phase III Trial of Neoadjuvant CT Plus Atezolizumab Followed by Adjuvant Atezolizumab for Stage II/III TNBC
Conference Coverage
Slideset
Congratulations: You achieved a completion on 04/09/2022

Released: December 18, 2024

Expires: December 16, 2025

Provided by

ProCE Banner

Provided by Clinical Care Options, LLC.

Supporters

Supported by educational grants from Lilly, Merck Sharp & Dohme LLC, and Novartis Pharmaceuticals Corporation.

Lilly

Merck Sharp & Dohme, LLC

Novartis Pharmaceuticals Corporation

*CCO is an independent medical education company that provides state-of-the-art medical information to healthcare professionals through conference coverage and other educational programs.